Skip to main content
CRS 2025 Annual Meeting & Exposition Main banner
Rate Poster

Nanomedicine and Nanoscale Delivery (Focus Group - NND)

(360) Hybrid nanoparticles with TGFβ1 EVs and cartilage-targeting liposomes for osteoarthritis treatment

Introduction: Osteoarthritis (OA) is a chronic degenerative joint disease causing pain and loss of mobility, impacting millions globally. Existing treatments, including corticosteroids and surgical interventions, focus primarily on symptom relief rather than regeneration. Mesenchymal stem cell-derived extracellular vesicles (EVs) are recognized for their regenerative potential but face limitations in stability and functional enhancement. Hybridizing EVs with functionalized nanoparticles is a promising approach to enhance therapeutic efficacy and overcomes limitations in OA treatment.

Learning Objectives:

  • Learn the limits of current OA treatments and the therapeutic promise of hybrid nanoparticles.
  • Explore the methodology for fabricating and validating EV-liposome hybrid nanoparticles.
  • Evaluate the in vivo efficacy of targeted hybrid nanoparticle treatments for OA.